Abstract
To fill the gap affecting the relevant heterogeneity of molecular testing and cancer care across Europe, the Women Against Lung Cancer Europe (WALCE) Association promoted the European Program for Routine testing of Patients with Advanced lung cancer (EPROPA) and provides a molecular screening platform for NSCLC samples characterization with the aim of increasing the detection of targetable drivers and optimizing patients’ access to clinical trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
